Indication
Recurrent Transformed Non-Hodgkin Lymphoma
7 clinical trials
12 products
8 drugs
Clinical trial
A Phase II Study Evaluating the Safety and Efficacy of the Combination of Zanubrutinib Plus Lisocabtagene Maraleucel for Richter's SyndromeStatus: Recruiting, Estimated PCD: 2025-12-31
Drug
cyclophosphamideProduct
FludarabineProduct
Lisocabtagene MaraleucelDrug
ZanubrutinibClinical trial
Phase I/II, Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) With Lenalidomide (R2-ICE) in Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Status: Active (not recruiting), Estimated PCD: 2021-09-24
Drug
AN0025Product
EtoposideProduct
IfosfamideProduct
LenalidomideDrug
VarlilumabClinical trial
A Phase 1 Study of Pembrolizumab Plus Vorinostat for Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin LymphomaStatus: Active (not recruiting), Estimated PCD: 2023-06-23
Product
PembrolizumabProduct
VorinostatClinical trial
Phase 1/Expansion Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory LymphomaStatus: Recruiting, Estimated PCD: 2025-03-01
Product
BelinostatClinical trial
Pilot/Feasibility Study of CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Following Autologous Hematopoietic Stem Cell Transplantation for Patients With Intermediate or High Grade B-Lineage Non-Hodgkin Lymphoma (B-NHL)Status: Recruiting, Estimated PCD: 2028-03-30
Product
TazemetostatClinical trial
A Two-Stage Phase 1 Open-Label Study of huJCAR014, CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells Bearing a Human Binding Domain, in Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Acute Lymphocytic LeukemiaStatus: Terminated, Estimated PCD: 2023-03-23
Drug
fludarabineClinical trial
A Pilot Phase I Study of Atezolizumab (MPDL3280A) in Combination With Immunogenic Chemotherapy (Gemcitabine-Oxaliplatin) and Rituximab for Transformed Diffuse Large B-Cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2025-06-30
Drug
AtezolizumabDrug
GemcitabineDrug
mFOLFOX6